Piper Sandler analyst Joseph Catanzaro upgraded ImmunoGen to Overweight from Neutral with a price target of $16, up from $6.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IMGN:
- ImmunoGen Skyrockets after Positive Topline Data
- ImmunoGen’s MIRASOL trial results represent best-case scenario, says Guggenheim
- ImmunoGen reports ‘positive’ results from Phase 3 MIRASOL trial
- ImmunoGen Rockets Up on Great Sales, Earnings
- ImmunoGen raises FY23 revenue excluding ELAHERE view to $45M-$50M